Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matrixx Eyes Antacids, Oral Care; Zicam Brand Drives 50% Sales Jump

This article was originally published in The Tan Sheet

Executive Summary

Matrixx is concentrating research spending on antacids, analgesics and oral care as possible areas for new product development
Advertisement

Related Content

Slow Cold Season Trims Matrixx Q4 Sales, But Net Loss Down By $2.5 Million
Slow Cold Season Trims Matrixx Q4 Sales, But Net Loss Down By $2.5 Million
Slow Cold Season Trims Matrixx Q4 Sales, But Net Loss Down By $2.5 Million
Low Brand Recognition Leaves Zicam Plenty Of Room To Grow
Low Brand Recognition Leaves Zicam Plenty Of Room To Grow
Low Brand Recognition Leaves Zicam Plenty Of Room To Grow
NACDS Marketplace In Brief
NACDS Marketplace In Brief
Zinc Gluconate Sprays Challenged In Lawsuits; Matrixx Defends Zicam Safety

Topics

Advertisement
UsernamePublicRestriction

Register

PS098779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel